ExeVir Bio Forges Ahead with Unique Next Generation COVID-19 Therapy and Appoints Dr. Jeanne Bolger as Chair of the Board of Directors
prnewswire.com
news
2022-10-20 07:00:00

Targeting final lead therapy selection, neutralizing all known previous and current SARS-CoV2 variants of concern by end 2022
Triple mode of action dengue fever program identified for development
Industry veteran with exceptional leadership experience to support ExeVir's new progressive pipeline against infectious diseases
GHENT, Belgium, Oct. 20, 2022 /PRNewswire/ -- ExeVir is developing robust therapies providing broad protection against infectious diseases, including coronaviruses. The company has identified high potential candidates harnessing its unique, modular Llama-derived antibody (VHH) technology platform to generate multi-specific antibodies for prophylaxis and treatment against COVID-19.
